Crossmark

Epigenomic and transcriptomic analyses define core cell types, genes and targetable mechanisms for kidney disease

Crossref DOI link: https://doi.org/10.1038/s41588-022-01097-w

Published Online: 2022-06-16

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Hongbo https://orcid.org/0000-0002-0733-8616
Doke, Tomohito https://orcid.org/0000-0003-1641-9351
Guo, Dong

Sheng, Xin https://orcid.org/0000-0002-3620-3577
Ma, Ziyuan https://orcid.org/0000-0002-1512-8993
Park, Joseph https://orcid.org/0000-0002-3313-641X
Vy, Ha My T.

Nadkarni, Girish N. https://orcid.org/0000-0001-6319-4314
Abedini, Amin

Miao, Zhen https://orcid.org/0000-0002-3255-9517
Palmer, Matthew

Voight, Benjamin F. https://orcid.org/0000-0002-6205-9994
Li, Hongzhe

Brown, Christopher D.

Ritchie, Marylyn D. https://orcid.org/0000-0002-1208-1720
Shu, Yan https://orcid.org/0000-0001-8492-1437
Susztak, Katalin https://orcid.org/0000-0002-1005-3726
Funding

Funding for this research was provided by:

Foundation for the National Institutes of Health (DK076077)

Foundation for the National Institutes of Health (DK105821)

Foundation for the National Institutes of Health (DK087635)
License Information

Text and Data Mining valid from 2022-06-16

Version of Record valid from 2022-06-16
More Information

Article History

Received: 13 August 2021

Accepted: 9 May 2022

First Online: 16 June 2022

Competing interests

: The laboratory of K.S. receives funding from GSK, Regeneron, Gilead, Merck, Boehringer Ingelheim, Bayer, Novartis Maze, Jnana, Ventus and Novo Nordisk. The funders had no influence on the data analysis. K.S. serves on the scientific advisory board (SAB) of Jnana pharmaceuticals and receives equity. M.D.R. serves on the SAB for Goldfinch Bio and Cipherome. The other authors declare no competing interests.

Document is current

Any future updates will be listed below